Search
Neurogene Inc
NGNEAdd to Watchlist
35.340USD
+1.460+4.31%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
551.86MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+4.31%
5 Days
+10.33%
1 Month
+28.60%
6 Months
+75.30%
Year to Date
+71.55%
1 Year
+75.91%
Key Figures
34.050Open
35.710High
363.22KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
2.33%Turnover Ratio
33.880Prev. Close
33.420Low
9.52MTurnover
LossP/E Static
2.32P/B
0.00%Div Yield TTM
-34.10%ROA
37.26652wk High
1.36Volume Ratio
-75.14MNet Profit
15.62MShares
-4.5448EPS TTM
1.70Beta
-37.25%ROE
14.65052wk Low
6.76%Amplitude
100.00%Gross Margin
551.86MMarket Cap
5.03Reward/Risk
4.63%Risk Rate
TradingKey Stock Score of Neurogene Inc
Currency: USD Updated: 2026-07-02Key Insights
Neurogene Inc's fundamentals are relatively weak, and its growth potential is high.Its valuation is considered fairly valued, ranking 72 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 80.00.In the medium term, the stock price is expected to trend up.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Neurogene Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Neurogene Inc Highlights
StrengthsRisks
Neurogene Inc. is a clinical-stage biotechnology company. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is in development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. It is also developing NGN-101 for the treatment of CLN5 Batten disease.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Undervalued
The company’s latest PE is -7.78, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 17.70M shares, decreasing 5.56% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 1.31K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.02.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
81.000
Target Price
+139.08%
Upside Space
Neurogene Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Neurogene Inc Info
Neurogene Inc. is a clinical-stage biotechnology company. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is in development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. It is also developing NGN-101 for the treatment of CLN5 Batten disease.
Ticker SymbolNGNE
CompanyNeurogene Inc
CEOMcMinn (Rachel L)
Websitehttps://www.neurogene.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Neurogene Inc (NGNE)?
The current price of Neurogene Inc (NGNE) is 35.34.
What is the symbol of Neurogene Inc?
The ticker symbol of Neurogene Inc is NGNE.
What is the 52-week high of Neurogene Inc?
The 52-week high of Neurogene Inc is 37.27.
What is the 52-week low of Neurogene Inc?
The 52-week low of Neurogene Inc is 14.65.
What is the market capitalization of Neurogene Inc?
The market capitalization of Neurogene Inc is 551.86M.
Is Neurogene Inc (NGNE) currently rated as Buy, Hold, or Sell?
According to analysts, Neurogene Inc (NGNE) has an overall rating of Buy, with a price target of 81.00.
What is the Earnings Per Share (EPS TTM) of Neurogene Inc (NGNE)?
The Earnings Per Share (EPS TTM) of Neurogene Inc (NGNE) is -4.24.